 BioLineRx Ltd. NASDAQ: BLRX TASE: BLRX, a clinical-stage biopharmaceutical company focused on oncology, announced today preliminary data from the triple combination arm of the ongoing Phase 2a COMBATKEYNOTE-202 study showing that the combination of BL-8040 a CXCR4 inhibitor, KEYTRUDA and chemotherapy shows high response and disease control rates in patients with metastatic pancreatic cancer. The data, summarized in an abstract published today, entitled, A Multi-Center Phase 2a Trial to Assess the Safety and Efficacy of BL-8040 a CXCR4 inhibitor in Combination with Pembrolizumab and Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma PDAC, will be presented and discussed as a proffered paper oral presentation on Friday, December 13 at the European Society of Medical Oncology Immuno-Oncology Congress ESMO IO 2019, which is being held December 11-14 at the Palexpo in Geneva, Switzerland. 